FDA panel looks beyond Activase

ROCKVILLE, Md. - An FDA advisory committee on Friday approved an accelerated dose regimen of Genentech Inc.'s Activase tPA for treatment of acute myocardial infarction, provided the FDA with general guidance on label inserts for the new dosage, and discussed design issues for future cardiovascular trials.

The Cardiovascular and Renal Drugs Advisory Committee recommended

Read the full 545 word article

How to gain access

Continue reading with a
two-week free trial.